Aerie Pharmaceuticals Inc Logo Image

Aerie Pharmaceuticals Inc

Aerie Pharmaceuticals Inc has reached its limit for report views.

Please check back to see if Aerie Pharmaceuticals Inc has upgraded their profile page to allow their financial information to be viewed. In the meantime, here are a few annual reports from similar companies.

About Aerie Pharmaceuticals Inc

51-200 Employees
Based in Bedminster, New Jersey

Aerie Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases. Its product candidates include Rhopressa, which is a once-daily eye drop that reduces intraocular pressure (IOP) in patients with glaucoma or ocular hypertension and is in Phase III registration trials; and Roclatan, a once-daily eye drop to reduce IOP that has completed Phase IIb clinical trial in patients with open-angle glaucoma and ocular hypertension.

Ticker:
AERI
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Drug Manufacturers - Major (See More Drug Manufacturers - Major Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol